By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Great Emphasis is Put on Research.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • AAIC - AI in AgriTech

    25.01.2022 - 26.01.2022, virtual

  • ROBOTICS Slovenia 2022

    15.02.2022 - 17.02.2022, Ljubljana, Slovenia

Austria Map

Find the perfect location for your company

Storage and distribution for Eastern Europe is more economical from Vienna than from Prague or Budapest. Because shipping business between the individual reform nations is barely developed, whereas neary every Eastern destination is serviced from Vienna several times a week.

Hewlett Packard Austria

Logo
More testimonials

news from the business location Austria

The path taken by immune cells

In order to combat infections and heal injuries as well as to fight against tumours, immune cells need to enter tissue.

IPCEI on Microelectronics – NXP Contributes Security Technology

Important Projects of Common European Interest (IPCEI) are large-scale innovation programmes in which several EU member states participate. They are designed to sustainably strengthen European value chains in critical technology sectors. Microelectronics comprises one such key technology. Within the context of the IPCEI on Microelectronics, NXP Gratkorn is focusing on the issue of “security,” thus contributing to Europe’s digital sovereignty and the resilience of its critical infrastructures.

More news All blog posts